StockData
Nurix Therapeutics, Inc. logo

Nurix Therapeutics, Inc. (NRIX) stock

NRIXNasdaqPharmaceutical PreparationsFiscal year ends November 30
Financials through Q3 FY2026, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 13, 2026Score 15/3073% below fair value
$14.10−0.14 (-0.98%)

Close on Nov 18, 2026Market cap $1.54BP/E 6.1Yield 0.00%

Nurix Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Nurix Therapeutics's free cash flow for the twelve months ending Aug 31, 2026 was $369.81M. For fiscal 2025 it was -$263.47M. The highest annual figure on record is -$1.05M in fiscal 2019.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Nov 30, 2025-$263.47M–
FY2024Nov 30, 2024-$181.86M–
FY2023Nov 30, 2023-$89.77M–
FY2022Nov 30, 2022-$172.05M–
FY2021Nov 30, 2021-$90.03M–
FY2020Nov 30, 2020-$4.63M–
FY2019Nov 30, 2019-$1.05M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2026CQ3 2026Aug 31, 2026$614.24M–
Q2 FY2026CQ2 2026May 31, 2026-$98.51M–
Q1 FY2026CQ1 2026Feb 28, 2026-$72.96M–
Q4 FY2025CQ4 2025Nov 30, 2025-$72.96M–
Q3 FY2025CQ3 2025Aug 31, 2025-$60.10M–
Q2 FY2025CQ2 2025May 31, 2025-$65.84M–
Q1 FY2025CQ1 2025Feb 28, 2025-$64.57M–
Q4 FY2024CQ4 2024Nov 30, 2024-$50.86M-311.0%
Q3 FY2024CQ3 2024Aug 31, 2024-$44.52M–
Q2 FY2024CQ2 2024May 31, 2024-$41.64M–
Q1 FY2024CQ1 2024Feb 29, 2024-$44.84M–
Q4 FY2023CQ4 2023Nov 30, 2023$24.10M–
Q3 FY2023CQ3 2023Aug 31, 2023-$43.59M–
Q2 FY2023CQ2 2023May 31, 2023-$19.55M–
Q1 FY2023CQ1 2023Feb 28, 2023-$50.73M–
Q4 FY2022CQ4 2022Nov 30, 2022-$40.52M–
Q3 FY2022CQ3 2022Aug 31, 2022-$49.73M–
Q2 FY2022CQ2 2022May 31, 2022-$35.70M–
Q1 FY2022CQ1 2022Feb 28, 2022-$46.10M-739.4%
Q4 FY2021CQ4 2021Nov 30, 2021-$31.77M–
Q3 FY2021CQ3 2021Aug 31, 2021-$31.84M–
Q2 FY2021CQ2 2021May 31, 2021-$33.63M–
Q1 FY2021CQ1 2021Feb 28, 2021$7.21M-82.2%
Q4 FY2020CQ4 2020Nov 30, 2020-$21.39M–
Q3 FY2020CQ3 2020Aug 31, 2020-$7.81M–
Q2 FY2020CQ2 2020May 31, 2020-$16.04M–
Q1 FY2020CQ1 2020Feb 29, 2020$40.61M–
Q4 FY2019CQ4 2019Nov 30, 2019-$13.70M–

More Nurix Therapeutics figures

See a number that looks wrong?